Restoring T-Cell Activity via PD-1 Blockade

How does PD-1 blockade restore T-cell activity in pembrolizumab-treated tumors?

PD-1 blockade restores T-cell activity by releasing PD-1-mediated suppression of preexisting exhausted tumor-infiltrating lymphocytes, enabling IFN-γ signaling that drives their clonal expansion, proliferation, and cytotoxic function.

Abstract

PD-1 blockade restores T-cell activity primarily through activation of preexisting tumor-infiltrating lymphocytes rather than recruitment of new T-cell clones. Across melanoma and head and neck cancer, restoration occurred via clonal expansion of exhausted CD8+ TILs with tissue-resident memory programs, increased CD8+ memory T cells, and enhanced granzyme B and Ki67 expression indicating proliferation and cytotoxic capacity. Mechanistically, this operated through release of PD-1-mediated suppression, enabling IFN-γ signaling pathways that drove T-cell proliferation, antigen presentation, and cytotoxic function. In head and neck cancer, restoration was further supported by enhanced K+ channel activity and Ca2+ signaling, which provided metabolic infrastructure for sustained T-cell activity. Restoration proceeded rapidly—within 5 weeks—through a biphasic pattern of immediate metabolic changes followed by durable functional enhancement. However, in pancreatic cancer, while PD-1 blockade successfully reactivated T cells as evidenced by increased cell cycle entry and IFNγ signature, concurrent upregulation of NF-κB signaling counteracted these benefits, demonstrating that successful restoration requires absence of alternative inhibitory pathways.

Baseline tumor immune composition determined restoration capacity across all cancer types studied. Responding tumors had higher baseline densities of CD8+, PD-1+, and PD-L1+ cells at tumor margins, preexisting ZNF683+CTX+ TILs, and T cell-inflamed gene expression signatures. The degree of T-cell restoration correlated directly with clinical outcomes, as proliferating intratumoral CD8+ T cells correlated with radiographic tumor reduction and enhanced functional measures associated with durable responses. These findings indicate that PD-1 blockade does not generate de novo antitumor responses but reinvigorates existing exhausted T cells, making adequate baseline T-cell infiltration a prerequisite for clinical benefit.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200

Papers screened using:

• Patient Population

• Pembrolizumab Treatment

• T-cell Functional Measurements

• Sample Analysis Type

• Study Design

• Immunological Data Inclusion

• Pembrolizumab-Specific Data

• Human Clinical Samples

• Cancer Patient Population

• n = 200 Papers screened out

• n = 190 Papers included for extraction

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex. We ran this query: “How does PD-1 blockade restore T-cell activity in pembrolizumab-treated tumors?” The search returned 200 total results from Elicit.

Screening

We screened in sources based on their abstracts that met these criteria:

• Patient Population: Does the study involve patients with any type of malignant tumor?
• Pembrolizumab Treatment: Does the study include pembrolizumab administered as monotherapy or combination therapy?
• T-cell Functional Measurements: Does the study measure T-cell functional parameters (such as proliferation, cytokine production, cytotoxic activity, or T-cell infiltration) before and/or after pembrolizumab treatment?
• Sample Analysis Type: Does the study include tumor tissue analysis or peripheral blood T-cell analysis?
• Study Design: Is the study a randomized controlled trial, cohort study, case-control study, case series with ≥5 patients, systematic review, or meta-analysis?
• Immunological Data Inclusion: Does the study report immunological or T-cell functional data?
• Pembrolizumab-Specific Data: Does the study include pembrolizumab data?
• Human Clinical Samples: Does the study use human tumor samples from pembrolizumab-treated patients?
• Cancer Patient Population: Does the study focus on cancer patients?

Data extraction

We asked a large language model to extract data points from each paper for various measures relevant to PD-1 blockade and T-cell restoration.

Results

Characteristics of Included Studies

All 10 sources examined T-cell restoration mechanisms following pembrolizumab treatment across diverse cancer types. The studies varied in cancer type, sample size, treatment protocols, and analytical approaches.

Mechanisms of T-Cell Restoration

• Reversal of Exhaustion and Memory Cell Expansion: PD-1 blockade restored T-cell function primarily through reversal of exhaustion in preexisting tumor-specific T cells.

• Molecular Signaling Pathways: Multiple molecular pathways mediated T-cell restoration. IFN-γ signaling emerged as a central driver across studies.

• Ion Channel and Metabolic Mechanisms: In HNSCC, pembrolizumab enhanced T-cell function through increased K+ channel activity and Ca2+ signaling.

• T-Cell Clonal Dynamics: Memory cell expansion occurred through restricted TCR beta chain usage and clonal expansion.

Predictive Biomarkers for T-Cell Restoration

• Baseline Immune Signatures: Baseline immune phenotypes strongly predicted restoration capacity.

• Gene Expression Profiles: A T cell-inflamed gene expression profile emerged as a pan-tumor predictive biomarker across multiple cancer types.

• Early Indicators of Reinvigoration: Several early indicators predicted successful T-cell restoration.

Anatomical Patterns of T-Cell Restoration

• Intratumoral vs. Circulating Compartments: T-cell restoration occurred in distinct patterns across anatomical compartments.

Temporal Dynamics of T-Cell Restoration

• Rapidity of Restoration: T-cell restoration occurred rapidly after pembrolizumab initiation.

• Duration and Persistence: Effects were prolonged and persisted after tumor resection.

Clinical Correlations

• Response Prediction and Survival: The degree of T-cell restoration strongly correlated with clinical outcomes.

Synthesis

The available evidence reveals consistent mechanisms of T-cell restoration across most cancer types studied, with the core restoration mechanism across responsive tumors involving the reinvigoration of existing exhausted T cells rather than the generation of new ones. Studies consistently identified baseline tumor immune composition as the primary determinant of restoration capacity.